Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 3, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WT1 Vaccine Doubles PFS in MPM Patients in Phase II Trial

 

A phase II clinical study of the WT1 cancer vaccine, developed by SELLAS Life Sciences Group, showed increased median overall survival in patients with malignant pleural mesothelioma.

Patients that received WT1 demonstrated an OS of 39 months compared to 18 months in the control arm. In addition, WT1 treatment resulted in a median progression-free survival of 11.5 months, more than double that of the control arm’s 5.5 months.

The double-blinded, randomized study compared WT1 analog peptides vaccine in combination with Montanide-adjuvant plus granulocyte-macrophage colony-stimulating factor, versus Montanide-adjuvant plus GM-CSF in patients with MPM who had previously completed combined modality therapy.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter